TORONTO, May 17, 2021 (GLOBE NEWSWIRE) — PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (CSE: PHRM) (OTCQB: PHRRF), a psychedelics biotech company, is pleased to announce that the U.S. Food and Drug Administration (“FDA”) has approved the Company’s Investigational New Drug (“IND”) application to proceed with a Phase 2 clinical trial to evaluate the safety…


Previous articleMindMed Receives FDA Type C Meeting Response for Project Lucy Phase 2b Clinical Trial
Next articleIntelGenx Announces Initial Closing of atai Investment